Clinical Trial Update: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial of SOM230 LAR in combination with bortezomib and dexamethasone for refractory or relapsed multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• SOM230 LAR (pasireotide long-acting release) (pasireotide)

Snippet

Sponsor: University of Pittsburgh | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma | Phase 2 | Status: WITHDRAWN